<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Glens Falls Business Journal</provider_name><provider_url>https://www.glensfalls.com/glensfallsbusinessjournal</provider_url><author_name>Samantha Racine</author_name><author_url>https://www.glensfalls.com/glensfallsbusinessjournal/author/samanthar/</author_url><title>Delcath Awaiting FDA Approval For Unique Chemotherapy Treatment Of Liver Cancer - Glens Falls Business Journal</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="c90oJOL41T"&gt;&lt;a href="https://www.glensfalls.com/glensfallsbusinessjournal/2012/08/delcath-awaiting-fda-approval/"&gt;Delcath Awaiting FDA Approval For Unique Chemotherapy Treatment Of Liver Cancer&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://www.glensfalls.com/glensfallsbusinessjournal/2012/08/delcath-awaiting-fda-approval/embed/#?secret=c90oJOL41T" width="600" height="338" title="&#x201C;Delcath Awaiting FDA Approval For Unique Chemotherapy Treatment Of Liver Cancer&#x201D; &#x2014; Glens Falls Business Journal" data-secret="c90oJOL41T" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://www.glensfalls.com/glensfallsbusinessjournal/wp-includes/js/wp-embed.min.js
/* ]]&gt; */
&lt;/script&gt;
</html><description>Delcath Systems, Inc. (NASDAQ: DCTH) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for the Company's proprietary chemosaturation system for use with melphalan hydrochloride in the treatment of patients with unresectable metastatic...</description></oembed>
